Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus

Phase 2

Completed

Conditions: Uterine Leiomyosarcoma
Recurrent Uterine Sarcoma

Interventions: Drug: sunitinib malate

First Posted Date: 2006-09-21

Last Posted Date: 2019-07-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 44

Registration Number: NCT00378911

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Phase 2

Completed

Conditions: Recurrent Breast Carcinoma
Stage IIIA Breast Cancer AJCC v7
Stage IV Breast Cancer AJCC v6 and v7
Stage III Breast Cancer AJCC v7
Stage IIIB Breast Cancer AJCC v7
Stage IIIC Breast Cancer AJCC v7

Interventions: Other: Laboratory Biomarker Analysis
Drug: Temsirolimus

First Posted Date: 2006-09-15

Last Posted Date: 2020-02-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 31

Registration Number: NCT00376688

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 1

Terminated

Conditions: B-cell Chronic Lymphocytic Leukemia
Contiguous Stage II Small Lymphocytic Lymphoma
Noncontiguous Stage II Small Lymphocytic Lymphoma
Stage I Chronic Lymphocytic Leukemia
Stage I Small Lymphocytic Lymphoma
Stage II Chronic Lymphocytic Leukemia
Stage III Chronic Lymphocytic Leukemia
Stage III Small Lymphocytic Lymphoma
Stage IV Chronic Lymphocytic Leukemia
Stage IV Small Lymphocytic Lymphoma

Interventions: Drug: alvocidib
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2006-09-15

Last Posted Date: 2013-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00377104

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Preventing Depression Recurrence in Diabetes

Phase 4

Completed

Conditions: Major Depression
Diabetes

First Posted Date: 2006-09-11

Last Posted Date: 2010-03-02

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 262

Registration Number: NCT00374426

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States

Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

Phase 3

Conditions: Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

Interventions: Drug: Placebo
Drug: Pregabalin

First Posted Date: 2006-09-01

Last Posted Date: 2011-03-16

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 318

Registration Number: NCT00371033

Locations: 🇺🇸
Charles R Drew University of Medicine & Science, Los Angeles, California, United States
🇨🇦
Queen's University, Kingston, Ontario, Canada
🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States

and more 8 locations

Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia

Phase 2

Completed

Conditions: Tobacco Use Disorder
Precancerous Condition
Stage I Non-small Cell Lung Cancer

Interventions: Drug: sulindac
Other: placebo

First Posted Date: 2006-08-29

Last Posted Date: 2014-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 61

Registration Number: NCT00368927

Locations: 🇨🇦
British Columbia, Vancouver, British Columbia, Canada
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States

and more 3 locations

VEGF Trap in Treating Patients With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer
Recurrent Breast Cancer
Stage IV Breast Cancer

Interventions: Biological: ziv-aflibercept

First Posted Date: 2006-08-29

Last Posted Date: 2014-05-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT00369655

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Lung
Adenosquamous Cell Lung Cancer
Bronchoalveolar Cell Lung Cancer
Large Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Squamous Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Biological: cetuximab
Drug: paclitaxel
Biological: bevacizumab

First Posted Date: 2006-08-29

Last Posted Date: 2015-09-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 110

Registration Number: NCT00368992

Locations: 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States

Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Adenocarcinoma of the Lung
Bronchoalveolar Cell Lung Cancer
Large Cell Lung Cancer
Stage II Non-small Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer

Interventions: Radiation: 3-dimensional conformal radiation therapy
Drug: paclitaxel
Biological: bevacizumab
Drug: carboplatin
Other: laboratory biomarker analysis

First Posted Date: 2006-08-29

Last Posted Date: 2014-03-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT00369551

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer

Phase 2

Completed

Conditions: Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Stage IB Cervical Cancer AJCC v6 and v7
Cervical Adenosquamous Carcinoma
Stage IIB Cervical Cancer AJCC v6 and v7
Stage III Cervical Cancer AJCC v6 and v7
Cervical Adenocarcinoma
Stage IIA Cervical Cancer AJCC v7

Interventions: Biological: Bevacizumab
Drug: Cisplatin
Radiation: External Beam Radiation Therapy
Radiation: Internal Radiation Therapy

First Posted Date: 2006-08-29

Last Posted Date: 2018-03-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00369122

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States
🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 103 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy